Showing 2871-2880 of 23149 results for "".
Rethinking SLE Treatment: Recent Approvals, Novel Targets, and What’s Next
https://reachmd.com/programs/living-rheum/sle-treatment-approvals-novel-targets/39846/Systemic lupus erythematosus (SLE) treatment is undergoing a transformative shift from broad immunosuppression to targeted, precision-based approaches. Dr. Marc Scherlinger joins Dr. Steve Jackson to provide a timely update on recent breakthroughs, including monoclonal antibodies, JAK and BTK inhibiRising Stimulant Use Among Patients with HIV: What 5 Years of Clinic Data Reveal
https://reachmd.com/programs/clinicians-roundtable/rising-stimulant-use-among-patients-with-hiv-what-5-years-of-clinic-data-reveal/32827/At Alabama’s only integrated infectious diseases and substance use clinic, clinicians are seeing a sharp rise in stimulant use among patients with opioid use disorder and HIV. That’s why they conducted a five-year retrospective study analyzing how comorbid stimulant use impacts clinical outcomes. WhNavigating Treatment Goals in IgAN: The Impact of ET-1 and Ang II
https://reachmd.com/programs/clinicians-roundtable/navigating-treatment-goals-in-igan-the-impact-of-et-1-and-ang-ii/37214/Given that the endothelin-1 (ET-1) and angiotensin II (Ang II) pathways contribute to the pathogenesis of IgA nephropathy (IgAN), it’s important to set treatment goals that prevent disease progression. Joining Dr. Charles Turck to discuss the role and impacts of ET-1 and Ang II and how we can achievImproving Postoperative Wound Outcomes Through Patient-Centered Education and Systemic Tools
https://reachmd.com/programs/clinicians-roundtable/improving-postoperative-wound-outcomes-through-patient-centered-education-and-systemic-tools/35839/Gaps in patient education and care coordination after surgery often hinder postoperative wound recovery. Join Dr. Karen Bauer as she discusses the importance of health literacy, access, and evidence-based care algorithms in engaging patients and support systems across the continuum. Dr. Bauer is a cReducing the Burden of gMG with a Novel B-Cell Therapy
https://reachmd.com/programs/neurofrontiers/reducing-the-burden-of-gmg-with-a-novel-b-cell-therapy/35496/Despite therapeutic advances, many generalized myasthenia gravis (gMG) patients continue to struggle with inadequately controlled disease, underscoring the importance of broadening treatment options that reduce disease burden while offering durable symptom control. With its novel mechanism of actionThe Latest on Antifungal Vaccines: Updates from IDWeek 2023
https://reachmd.com/programs/clinicians-roundtable/the-latest-on-antifungal-vaccines-updates-from-idweek-2023/16136/What are the latest updates on antifungal vaccines we need to be aware of? Find out with this recap of a session at IDWeek 2023.Reducing Relapse for Schizophrenia Patients: A Look at LAI Antipsychotics
https://reachmd.com/programs/neurofrontiers/reducing-relapse-for-schizophrenia-patients-a-look-at-lai-antipsychotics/13326/What kind of impact might long-acting injectable antipsychotics have on the frequency of relapse and non-adherence among patients with schizophrenia?How Spa Dermatology Has Evolved for the Better & Worse
https://reachmd.com/programs/dermconsult/how-spa-dermatology-has-evolved-for-the-better-worse/12668/Spa dermatology has morphed over the last 20 to 30 years, but not all of those changes benefited our patients.The Pediatric Perspective of Crohn’s Disease & Ulcerative Colitis
https://reachmd.com/programs/gi-insights/the-pediatric-perspective-of-crohns-disease-ulcerative-colitis/12645/The drug selection for pediatric patients with Crohn’s disease and ulcerative colitis is largely empirical. But is this about to change?The Impacts of Gender Bias & Trauma on GI Patients
https://reachmd.com/programs/gi-insights/the-impacts-of-gender-bias-trauma-on-gi-patients/12467/Gender bias and trauma are prevalent issues facing GI patients. Here’s how they can impact our patients and our own approach to care.